[1]张旭裕,钟诚,蒲有为,等.基于微阵列和生物信息学分析的茯苓多糖对Lewis肺癌小鼠差异表达miRNA的影响[J].中国中医药信息杂志,2021,28(11):76-82.[doi:10.19879/j.cnki.1005-5304.202104099]
 ZHANG Xuyu,ZHONG Cheng,PU Youwei,et al.Effects of Poria Polysaccharide on miRNA Changes of Lewis Lung Cancer Mice Based on miRNA qPCR Arrays and Bioinformatics Analysis[J].zhongguo zhongyiyao xinxi zazhi,2021,28(11):76-82.[doi:10.19879/j.cnki.1005-5304.202104099]
点击复制

基于微阵列和生物信息学分析的茯苓多糖对Lewis肺癌小鼠差异表达miRNA的影响

参考文献/References:

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians,2018,68(6):394-424.

[2] FANG J Y, DONG H L, WU K S, et al. Characteristics and prediction of lung cancer mortality in China from 1991 to 2013[J]. Asian Pac J Cancer Prev,2015,16(14):5829-5834.

[3] EFFERTH T, LI P, KONKIMALLA V, et al. From traditional Chinese medicine to rational cancer therapy[J]. Trends in Molecular Medicine,2007,13(8):353-361.

[4] LI X, HE Y, ZENG P, et al. Molecular basis for Poria cocos mushroom polysaccharide used as an antitumourdrug in China[J]. Journal of Cellular and Molecular Medicine,2019,23(1):4-20.

[5] NIE C, ZHU P, MA S, et al. Purification, characterization and immunomodulatory activity of polysaccharides from stem lettuce[J]. Carbohydrate Polymers,2018,188:236-242.

[6] XIE Y, WANG L, SUN H, et al. Immunomodulatory, antioxidant and intestinal morphology-regulating activities of alfalfa polysaccharides in mice[J]. International Journal of Biological Macromolecules,2019,133:1107-1114.

[7] YIN M, ZHANG Y, LI H. Advances in research on immunoregulation of macrophages by plant polysaccharides[J]. Frontiers in Immunology,2019,10:145.

[8] ZHAO Y, HU W, ZHANG H, et al. Antioxidant and immunomodulatory activities of polysaccharides from the rhizome of Dryopteris crassirhizoma Nakai[J]. International Journal of Biological Macromolecules,2019,130:238-244.

[9] 魏科,陈勇超,周家豪,等.茯苓多糖辅助抗肺癌及免疫调节作用研究[J].中华中医药杂志,2020,35(10):4937-4940.

[10] 蒋逸凡,金梦圆,周选围.茯苓多糖及其免疫调节功能研究进展[J].食用菌学报,2021,28(2):130-139.

[11] 蒋瑜.茯苓的抗乳腺癌活性及作用机制的研究[D].无锡:江南大学, 2020.

[12] HAN F, HE J X, LI F, et al. Emerging roles of microRNAs in EGFR-targeted therapies for lung cancer[J]. Biomed Res Int,2015, 2015:672759.

[13] JIA R, WANG C. MiR-29b-3p reverses cisplatin resistance by targeting COL1A1 in non-small-cell lung cancer A549/DDP cells[J]. Cancer Manag Res,2020,12:2559-2566.

[14] YOU Y H, WANG X G, XU M, et al. Expression and clinical significance of miR-139-5p in non-small cell lung cancer[J]. J Int Med Res,2019,47(2):867-874.

[15] HUANG N, GUO W, REN K, et al. LncRNA AFAP1-AS1 supresses miR-139-5p and promotes cell proliferation and chemotherapy resistance of non-small cell lung cancer by competitively upregulating RRM2[J]. Front Oncol,2019,9:1103.

[16] LIU R, ZHANG Y S, ZHANG S, et al. MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1[J]. Eur Rev Med Pharmacol Sci,2019,23(2):679-689.

[17] SHEN Y Y, CUI J Y, YUAN J, et al. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2[J]. Eur Rev Med Pharmacol Sci,2018,22(17):5554- 5561.

[18] LOVERING R C, CAMON E B, BLAKE J A, et al. Access to immunology through the gene ontology[J]. Immunology,2008,125(2):154-160.

[19] LI B, DING C M, LI Y X, et al. MicroRNA?/span>145 inhibits migration and induces apoptosis in human non-small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway[J]. Oncol Rep,2018,40(5):2944-2954.

[20] ZHANG W L, ZHAO Y N, SHI Z Z, et al. Lutein inhibits cell growth and activates apoptosis via the PI3K/AKT/mTOR signaling pathway in A549 human non-small-cell lung cancer cells[J]. J Environ Pathol Toxicol Oncol,2018,37(4):341-350.

[21] CHEN T, XIAO Q, WANG X, et al. MiR-16 regulates proliferation and invasion of lung cancer cells via the ERK/MAPK signaling pathway by targeted inhibition of MAPK kinase 1 (MEK1)[J]. J Int Med Res,2019,47(10):5194-5204.

[22] AGUSTL A, MORLA M, SAULEDA J, et al. NF-κB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight[J]. Thorax,2004,59(6):483-487.

[23] DHAR S K, LYNN B C, DAOSUKHO C, et al. Identification of nucleophosmin as an NF-κB co-activator for the induction of the human SOD2 gene[J]. J Biol Chem,2004,279(27):28209-28219.

[24] BEZBRADICA J S, MEDZHITOV R. Integration of cytokine and heterologous receptor signaling pathways[J]. Nat Immunol,2009, 10(4):333-339.

相似文献/References:

[1]曾柏荣,王理槐,孙银辉.扶正口服液对气阴两虚型Ⅲ-Ⅳ期肺癌患者化疗毒副反应的影响[J].中国中医药信息杂志,2013,20(12):73.[doi:10.3969/j.issn.1005-5304.2013.12.029]
 [J].zhongguo zhongyiyao xinxi zazhi,2013,20(11):73.[doi:10.3969/j.issn.1005-5304.2013.12.029]
[2]昝俊峰,徐斌,於小波,等.全国20个主要产地茯苓质量分析比较研究[J].中国中医药信息杂志,2010,17(8):34.[doi:10.3969/j.issn.1005-5304.2010.08.016]
 ZAN Jun-feng,XU Bin,YU Xiao-bo,et al.Comparative Study on the Quality of Poria Cocos from 20 Different Origin Places[J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):34.[doi:10.3969/j.issn.1005-5304.2010.08.016]
[3]范宏宇.肺癌咯血的中医治疗[J].中国中医药信息杂志,2009,16(5):82.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):82.
[4]王芬,周而复,陈文强,等.中晚期肺癌中医证候与患者生存质量关系的分析[J].中国中医药信息杂志,2007,14(2):21.
 WANG Fen,ZHOU Er-ful,CHEN Wen-qiang,et al.Analysis on the Correlation between the Principa1 Components of TCM Symptoms and the Quality of Life of the Middle-Advanced Stages Lung Caner Patients[J].zhongguo zhongyiyao xinxi zazhi,2007,14(11):21.
[5]王芳,花宝金,李丛煌.肺瘤平膏Ⅱ号合并化疗治疗非小细胞肺癌临床观察[J].中国中医药信息杂志,2009,16(9):53.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):53.
[6]李道睿,张培彤,胡晓梅,等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志,2007,14(3):19.
 LI Dao-rui,ZHANG Pei-tong,HU Xiao-mei,et al.Investigation of Distributing Characteristics of Blood Stasis Syndrome on 300 Cases of Advanced Stage Lung Cancer Patiens[J].zhongguo zhongyiyao xinxi zazhi,2007,14(11):19.
[7]闫向勇,孟庆常,燕忠生,等.岩舒注射液对肺癌放射性肺损伤的保护作用[J].中国中医药信息杂志,2008,15(4):82.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):82.
[8]樊春晓,崔蒙,于琦,等.基于中医药数据库的中医药治疗肺癌临床文献分析[J].中国中医药信息杂志,2011,18(5):27.[doi:10.3969/j.issn.1005-5304.2011.05.010]
 FAN Chun-xiao,CUI Meng,YU Qi,et al.Analysis on Clinical Literature of TCM for Lung Cancer in Recent Decade of Domestic Journals[J].zhongguo zhongyiyao xinxi zazhi,2011,18(11):27.[doi:10.3969/j.issn.1005-5304.2011.05.010]
[9]山广志,王海涛.黄枇烟吸入法治疗肺癌临床观察[J].中国中医药信息杂志,2011,18(8):77.[doi:10.3969/j.issn.1005-5304.2011.08.035]
[10]齐元富,李秀荣,李慧杰.大黄?虫丸治疗肺癌临床研究[J].中国中医药信息杂志,2011,18(11):15.[doi:10.3969/j.issn.1005-5304.2011.11.006]
 QI Yuan-fu,LI Xiu-rong,LI Hui-jie.Clinical Study on Lung Cancer Treated by Dahuang Zhechong Wan[J].zhongguo zhongyiyao xinxi zazhi,2011,18(11):15.[doi:10.3969/j.issn.1005-5304.2011.11.006]

备注/Memo

基金项目:国家自然科学基金(81773940、81473388)

更新日期/Last Update:

2021-10-21